Axsome Therapeutics Showcases Neuroscience Data at Psych Congress 2024

Axsome Therapeutics, Inc., a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, announced on October 29, 2024, that it will present seven key studies from its neuroscience portfolio at the Psych Congress 2024 in Boston, Massachusetts, from October 29 to November 2.

The company's presentations will cover a variety of CNS conditions, with detailed findings from several clinical trials.

**Major Depressive Disorder (MDD)**

Axsome will highlight data on AXS-05 (Auvelity®), a treatment for major depressive disorder. The pooled data from two six-week controlled trials (GEMINI and ASCEND) will be presented by Dr. Craig Chepke from SUNY Upstate Medical University. These sessions are scheduled for October 31 and November 1, from 1:30 to 3 p.m. ET, under poster number 171.

Additionally, Dr. Roger McIntyre, a professor at the University of Toronto, will present two related studies. The first examines AXS-05's effectiveness in improving anhedonia (lack of pleasure) and interest-activity symptoms associated with MDD, as well as the related improvements in functional impairment. This presentation will also be held on October 31 and November 1, during the same time slots, under poster number 172.

Dr. McIntyre will also discuss real-world treatment experiences and expectations based on symptom severity among MDD patients. His findings will be shared on October 31 and November 1 at the same times, under poster number 198.

**Alzheimer’s Disease Agitation**

Jeffrey Cummings, MD, ScD, from the UNLV Department of Brain Health, will present the clinical profile of AXS-05 in treating agitation related to Alzheimer’s disease. This presentation will also take place on October 31 and November 1, from 1:30 to 3 p.m. ET, under poster number 45. The results stem from the Phase 2/3 development program.

**OSA and Narcolepsy**

Axsome will share findings from their research on solriamfetol, a medication for excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea (OSA) who also report anxiety and depression. Dr. Ulf Kallweit from the University Witten/Herdecke in Germany will present these findings on October 31 and November 1, at the same time slots, under poster number 20.

**Cognition**

Two presentations will address the effects of solriamfetol on cognition. Dr. Yaroslav Winter from the Mainz Comprehensive Epilepsy and Sleep Medicine Center at Johannes Gutenberg-University in Germany will lead both presentations. The first study, focusing on patients with obstructive sleep apnea and excessive daytime sleepiness, will be presented on October 31 and November 1, from 1:30 to 3 p.m. ET, under poster number 92. The second study will explore the cognitive effects of solriamfetol in patients with narcolepsy, presented during the same times under poster number 164.

**About Axsome Therapeutics**

Axsome Therapeutics, Inc. is dedicated to developing novel therapies for CNS conditions with limited treatment options. By focusing on innovative mechanisms of action, the company aims to transform treatment approaches and significantly improve patient outcomes. Axsome is committed to providing new therapeutic options for physicians and enhancing the quality of life for patients.